GlassScriptPhysician profile
Eduardo A Reyes
NPI 1689850182
$11,164.12
in general payments reported to CMS, 2019-2025
51 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $1,417 · 2021: $1,768 · 2022: $1,791 · 2023: $1,651 · 2024: $1,637 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,962.21 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $961.25 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $817.31 | 2019-2025 | |
| Novo Nordisk INC | $796.53 | 2019-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $709.63 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $602.84 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $562.18 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $540.17 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $530.82 | 2019-2023 | |
| Abbvie INC. | $505.65 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.43 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $486.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $424.94 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Amgen INC. | $360.06 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $342.46 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.74 | 2019-2025 | Xifaxan, Trulance |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.